TBTravis W. Bainbridge

Travis W. Bainbridge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Travis W. Bainbridge has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GYDE: A collaborative drug discovery platform for AI-powered protein design and engineering

    by Kiran Mukhyala, Thomas Down, Mateusz Warowny, April Walker, Luigi D'AScenzo, Donald Lee, Zhenru Zhou, Shengya Cao, Travis Bainbridge, John Nicoludus, et al.

    As computational tools and machine learning models for protein sciences continue to advance and proliferate, bench scientists face increasing technical challenges adopting these tools for specific applications such as drug discovery. Here we present GYDE (Guide Your Design and Engineering), an open-source, versatile, and web-based collaboration platform designed to make computational analyses of proteins and antibodies easily accessible to bench scientists. GYDE enables the exploration of sequence-structure-function relationships through a tightly integrated visual interface, offering researchers a comprehensive exploration of protein functional determinants either via real assay data or computational tools. GYDE’s intuitive interface facilitates seamless access to cutting-edge AI models for protein and antibody structure prediction, design, and downstream analyses. The flexible and easy addition of new tools and models is facilitated by the use of the Slivka compute API. The platform supports saved sessions that enable researchers to easily share their findings with other users, fostering a more collaborative scientific community. GYDE is freely available for protein scientists in academia and industry to build drug discovery analytics platforms customized to their needs.

  • Open Access

    Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy

    by Travis W Bainbridge, Lifen Wang, Marina Moskalenko, Robert Herrera, Maciej T Paluch, Dawei Sun, Kazi Tasneem, Harpinder Saini, Manal Sadek, Mandy Kwong, et al.

    Background: The pro-inflammatory cytokine, interleukin-18 (IL-18), plays an instrumental role in bolstering anti-tumor immunity. However, the therapeutic application of IL-18 has been limited due to its susceptibility to neutralization by IL-18 binding protein (IL-18BP), short in vivo half-life, and unfavorable physicochemical properties. Methods: In order to overcome the poor drug-like properties of IL-18, we installed an artificial disulfide bond, removed the native, unpaired cysteines, and fused the stabilized cytokine to an IgG Fc domain. The stability, potency, pharmacokinetic and pharmacodynamic properties as well as efficacy of disulfide-stabilized IL-18 Fc-fusion (dsIL-18-Fc) were assessed via in vitro and in vivo studies. Results: The stability and mammalian host cell production yields of dsIL-18-Fc were improved, compared to the wild-type (WT) cytokine, while maintaining its biological potency and interactions with IL-18 receptor α (IL-18Rα) and IL-18BP. Recombinant fusion of the cytokine to an IgG Fc domain provided extended half-life. Notably, despite maintaining sensitivity to IL-18BP, dsIL-18-Fc was effective at activating both T and natural killer (NK) cells, and elicited a strong anti-tumor response, either as a single agent, or in conjunction with anti-programmed cell death-ligand 1 (anti-PD-L1) therapy. Conclusions: We engineered IL-18 for reinforced stability, extended half-life, and improved manufacturability. The therapeutic benefit of dsIL-18-Fc, coupled with a more favorable manufacturability profile and enhanced drug-like properties, underscores the potential utility of this engineered cytokine in cancer immunotherapy.


  • Open Access

    Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations

    by Jérémie Decalf, Evangeline Toy, Dongping He, Radhika Kenkre, Amy M. Berkley, Devon Wong, Mandy Kwong, Yee-Seir Kee, Yue Sun, Srividya Myneni, et al.


  • Open Access

    A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule

    by Iraj Hosseini, Brett Fleisher, Jennifer Getz, Jérémie Decalf, Mandy Kwong, Meric Ovacik, Travis W. Bainbridge, Christine Moussion, Gautham K. Rao, Kapil Gadkar, et al.

    FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different dose levels. A minimal physiologically based PK/PD model with expansion-enhanced target-mediated drug disposition (TMDD) was developed to integrate the molecule’s mechanism of action, as well as the complex preclinical and clinical PK/PD data, to support the preclinical-to-clinical translation of FLT3L-Fc. In addition to the preclinical PK data of FLT3L-Fc in cynomolgus monkeys, clinical PK and PD data from other FLT3-agonist molecules (GS-3583 and CDX-301) were used to inform the model and project the expansion profiles of conventional DC1s (cDC1s) and total DCs in peripheral blood. This work constitutes an essential part of our model-informed drug development (MIDD) strategy for clinical development of FLT3L-Fc by projecting PK/PD in healthy volunteers, determining the first-in-human (FIH) dose, and informing the efficacious dose in clinical settings. Model-generated results were incorporated in regulatory filings to support the rationale for the FIH dose selection.


  • IL-1R1–dependent signaling coordinates epithelial regeneration in response to intestinal damage

    by Christian B. Cox, Elaine E. Storm, Varun N. Kapoor, Joseph Chavarria-Smith, David L. Lin, Lifen Wang, Yun Li, Noelyn Kljavin, Naruhisa Ota, Travis W. Bainbridge, et al.

    Repair of the intestinal epithelium is tightly regulated to maintain homeostasis. The response after epithelial damage needs to be local and proportional to the insult. How different types of damage are coupled to repair remains incompletely understood. We report that after distinct types of intestinal epithelial damage, IL-1R1 signaling in GREM1+ mesenchymal cells increases production of R-spondin 3 (RSPO3), a Wnt agonist required for intestinal stem cell self-renewal. In parallel, IL-1R1 signaling regulates IL-22 production by innate lymphoid cells and promotes epithelial hyperplasia and regeneration. Although the regulation of both RSPO3 and IL-22 is critical for epithelial recovery from Citrobacter rodentium infection, IL-1R1–dependent RSPO3 production by GREM1+ mesenchymal cells alone is sufficient and required for recovery after dextran sulfate sodium–induced colitis. These data demonstrate how IL-1R1–dependent signaling orchestrates distinct repair programs tailored to the type of injury sustained that are required to restore intestinal epithelial barrier function.


  • Open Access

    Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ

    by William J. Meilandt, Janice A. Maloney, Jose Imperio, Guita Lalehzadeh, Tim Earr, Susan Crowell, Travis W. Bainbridge, Yanmei Lu, James A. Ernst, Reina N. Fuji, et al.

    Background: Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglobulin G4 monoclonal antibody that has been shown to bind to synthetic monomeric and aggregated Aβ in vitro; however, less is known about the binding characteristic in vivo. In this study, we evaluated the binding patterns of crenezumab to synthetic and native forms of Aβ both in vitro and in vivo. Methods: Crenezumab was used to immunoprecipitate Aβ from synthetic Aβ preparations or brain homogenates from a PS2APP mouse model of AD to determine the forms of Aβ that crenezumab interacts with. Following systemic dosing in PS2APP or nontransgenic control mice, immunohistochemistry was used to localize crenezumab and assess its relative distribution in the brain, compared with amyloid plaques and markers of neuritic dystrophies (BACE1; LAMP1). Pharmacodynamic correlations were performed to investigate the relationship between peripheral and central target engagement. Results: In vitro, crenezumab immunoprecipitated Aβ oligomers from both synthetic Aβ preparations and endogenous brain homogenates from PS2APP mice. In vivo studies in the PS2APP mouse showed that crenezumab localizes to regions surrounding the periphery of amyloid plaques in addition to the hippocampal mossy fibers. These regions around the plaques are reported to be enriched in oligomeric Aβ, actively incorporate soluble Aβ, and contribute to Aβ-induced neurotoxicity and axonal dystrophy. In addition, crenezumab did not appear to bind to the dense core region of plaques or vascular amyloid. Conclusions: Crenezumab binds to multiple forms of amyloid β (Aβ), particularly oligomeric forms, and localizes to brain areas rich in Aβ oligomers, including the halo around plaques and hippocampal mossy fibers, but not to vascular Aβ. These insights highlight a unique mechanism of action for crenezumab of engaging Aβ oligomers.